Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist
- 1 March 2019
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 166, 232-242
Abstract
No abstract availableKeywords
Funding Information
- Nature Science Foundation of China (81672559, 81311120299, 81271844)
- CAMS Innovation (CAMS-I2M-1-012 ZJM)
- National key research and development program (2016YFA0201500)
This publication has 30 references indexed in Scilit:
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate CancerDiscover Oncology, 2014
- Androgen receptor signaling in prostate cancerCancer and Metastasis Reviews, 2014
- CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agentsNature Reviews Urology, 2013
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Cancer Discovery, 2013
- Shifting from the single to the multitarget paradigm in drug discoveryDrug Discovery Today, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancerProceedings of the National Academy of Sciences, 2011
- Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 SynthaseJournal of Chemical Information and Modeling, 2010
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003